Background Chromosomal trisomies are associated with advancing maternal age. In Ireland, information on the total prevalence and outcome of trisomy affected pregnancies is unavailable. This study aimed to ascertain more precise data on Trisomies 21, 18 and 13 in a large Irish region during the period 2011-2013.
Introduction
Advancing maternal age is the primary risk factor for trisomy affected pregnancies. 1 The most prevalent chromosomal trisomies are Trisomies 21, 18 and 13 (Down, Edwards and Patau syndromes). The risk of an affected pregnancy rises with the mother's age particularly aged 30-35 onwards. In Ireland, by 2013, the proportion of total births to mother's aged 30+ had risen to 68.5%, 2 compared with 50.5% in England and Wales. 3 This disparity is also evident between Ireland and Europe; births to mother's aged 35+ years in the EU rose from 10% to 22% 4 between 2003 and 2013 while births in Ireland in the same age group rose from 18% to 32%.
The risk of a having a trisomy affected pregnancy in Ireland is therefore much higher due to the maternal age profile. In addition, whereas a higher proportion of trisomy affected pregnancies in Europe end in termination, 5 a pregnancy in the Republic of Ireland can only be legally terminated in circumstances where there is a real and substantial risk to the life of the mother, and termination of pregnancy for foetal anomaly (TOPFA) is not permitted under the Irish constitution. Cultural and social norms tend to differ in Ireland compared with other European countries and many women with a pregnancy complicated by a trisomy diagnosis decide to continue with their pregnancy and give birth. However, an unknown proportion of women with trisomy affected pregnancies travel from Ireland to other jurisdictions for a TOPFA, and consequently, the total number of trisomy affected pregnancies in the Republic of Ireland is also unknown.
The aim of this study was to more precisely determine the number and outcome of trisomy affected pregnancies in a large populous region in the East of Ireland, and to calculate the age-related risk of having an affected pregnancy, and extrapolate to estimate the numbers of trisomy affected pregnancies in the Republic of Ireland as a whole.
Methods
The study was coordinated by the Dublin EUROCAT Registry, the three Dublin maternity hospitals and the Department of Clinical Genetics (DCG) for the region. The Dublin EUROCAT Registry is a regional population-based congenital anomaly registry in the East of Ireland (counties Dublin, Wicklow and Kildare) with a combined annual livebirth total of over 27 000 births, representing 38% of births in the Republic of Ireland in 2013. The registry is a member of the European network of congenital anomaly registries (EUROCAT-www.eurocat-network.eu). Trisomies 21, 18 and 13 were studied and all karyotypes were included. The time frame was the 3-year period from 2011 to 2013. A case was defined as a trisomy affected pregnancy where the outcome was a live birth, foetal death (stillbirth or miscarriage), a TOPFA or likely TOPFA. Where the outcome was a foetal death or TOPFA, gestation at diagnosis was used to estimate the expected year of delivery. For cases prenatally diagnosed at an unknown time of gestation, the prenatal diagnostic test date was used as a proxy measure of gestation time.
The region's population is primarily urban, and includes the capital city, Dublin. The birth population reflects that of the state, with 68.6% of births born to mother's aged 30+ years and 31.8% to mother's aged 35+ years in 2013, compared with 68.7% and 32.0%, respectively, for births nationally. The three maternity hospitals in the region are university teaching hospitals located in Dublin, each with a prenatal assessment facility. Data were gathered from the maternity and paediatric hospitals with demographic, diagnostic, delivery, clinical outcome, obstetric and family history variables. Karyotyping information was available from the DCG. Multiple sources of ascertainment were used and case records were also reviewed.
Births and stillbirths registration data were provided by the Central Statistics Office, though there is no official recording of TOPFA information. In this study, clinical records confirmed in some cases that a TOPFA was obtained abroad following prenatal diagnosis. In other cases, the outcome following prenatal diagnosis was unknown where women did not give birth in the hospital booked for antenatal care. Based on consultations with clinicians, the assumption was made that these women were very likely to have obtained a TOPFA abroad as it was usual that births other than a TOPFA would entail communication between the hospital of birth and clinicians in Ireland. We therefore defined a TOPFA as a trisomy case where the outcome of the pregnancy was known to be a termination confirmed by a clinician, or a prenatally diagnosed case where the outcome was unknown but clinically very likely to have been a TOPFA.
The denominator population was the number of live births and stillbirths in the study region for the 3-year study period. 2 The corresponding national births were used for extrapolating national trisomy rates. During the 3 years, there were 80 894 total births (live births + stillbirths) in the East of Ireland. The total numbers of births in each of the 3 years were as follows: 27 715 in 2011, 27 140 in 2012 and 26 039 in 2013. In the Republic of Ireland as a whole, there were a total of 215 250 births during the period. In calculating rates for specific maternal age groups, the denominator used was live births only, as age was not available for stillbirth denominators. Early and late foetal deaths were defined as those occurring before or after 20 weeks gestation, respectively. The total prevalence rate was defined as the sum of live birth, foetal death and TOPFA cases per 10 000 births. 'Perinatal mortality' was defined as late foetal deaths and early neonatal deaths with a specific trisomy, divided by live births and late foetal deaths with the specific trisomy. The 'perinatal mortality' rate was calculated as late foetal deaths and early neonatal deaths with a specific trisomy, divided by total live births and late foetal deaths multiplied by 10 000.
The study was subject to a successful application for ethical approval by a major paediatric hospital before commencement.
Results
There were 394 cases of Trisomies 21, 18 and 13 ascertained during the 3-year period (Table 1) . Of the total, 73.4% (289/394) were diagnosed with Trisomy 21, 19.0% (75/394) with Trisomy 18 and 7.6% (30/394) with Trisomy 13. The total prevalence rate per 10 000 births was 48.7 for the 3-year period. The rate for Trisomy 21 was 35.7, and 9.3 and 3.7 for Trisomies 18 and 13, respectively. Of the total 394 cases, the mother's ethnicity was available for 57% (225/ 394), of whom 67.5% (152/225) were Irish, with <10% of any other ethnic origin. Ethnicity was available for 76.3% (187/245) of non TOPFA cases, of whom 66.8% (125/187) were Irish.
The median age of the mother for all trisomies was 37.0 years; the median age for Trisomy 21 was 38.0 years and for Trisomies 18 and 13, the median ages were 38.0 and 35.5 years, respectively. At least 70% of Trisomy 21 and Trisomy 18 pregnancies were to mother's aged 35+ years. Figure 1 shows that the overall trisomy rate per 10 000 births almost doubled (from 15.2 to 28.5) for women in the 30-34 age group compared with women aged 25-29, primarily due to the predominance of Trisomy 21. The rate increased steeply with each further advancing age group. Table 2 shows that by individual trisomy type, the increased rate was more apparent from 30+ years for Trisomy 21 and Trisomy 13, but from 35+ years for Trisomy 18. The highest rate was in the 40+ age group for all trisomies. Correspondingly, the overall risk of having a trisomy affected pregnancy increased through each advancing age group.
Prenatal diagnosis
Information on prenatal diagnosis was available for 96.2% (379/394) of cases, the 15 cases not diagnosed prenatally were live births whose mother's had received maternity care outside the study region. There was a prenatal diagnosis in 60% (236/394) of all trisomy cases, 47% (136/289) of Trisomy 21 cases, 96% (72/75) and 93% (28/30) of Trisomies 18 and 13 cases, respectively. There was a significantly higher proportion of Trisomies 18/13 combined diagnosed prenatally compared with Trisomy 21 (χ 2 = 67.2, df = 1, P < 0.001). However, for mother's aged under The gestational age at prenatal diagnosis was known in 68.6% (162/236) of all trisomies, of whom 50.6% (82/ 162) were diagnosed before 20 weeks. For Trisomy 21, the gestational age at prenatal diagnosis was known in 67.6% (92/136), of whom 56.5% (52/92) were diagnosed before 20 weeks. For Trisomy 18, the gestational age at prenatal diagnosis was known in 70.1% (51/72), of whom 41.2% (21/51) were diagnosed before 20 weeks, and for Trisomy 13, the gestational age at prenatal diagnosis was known in 67.9% (19/28), of whom 47.4% (9/19) were diagnosed before 20 weeks.
Outcome of pregnancy Table 3 shows the pregnancy outcome by type of trisomy. Half of all cases were live births. For Trisomy 21, the outcome was a live birth in 61.2% (177/289) of cases, with less that a third where the outcome was a TOPFA. The opposite occurred with Trisomies 18 and 13, in which the outcome was a TOPFA in more than a half of cases. Where there was a prenatal diagnosis, the pregnancy outcome was a TOPFA in 66% (90/136) of Trisomy 21 cases, 54% (39/72) of Trisomy 18 cases and 71% (20/28) of Trisomy 13 cases. There was no statistically significant difference between maternal age groups and the likelihood of a TOPFA outcome for any of the trisomy types.
All late foetal deaths were stillbirths. Perinatal mortality associated with all trisomies was 21.5% (50/233). Perinatal mortality for Trisomy 21 was 9.9% (19/193), and for Trisomies 18 and 13, the perinatal mortalities were 86.7% (26/30) and 50% (5/10), respectively. The perinatal mortality rate for all trisomies was 6.2 per 10 000. The perinatal mortality rate for Trisomy 21 was 2.4, and was 3.2 and 0.6 for Trisomies 18 and 13, respectively.
The parity of the mother was known in 98.7% (389/394) of cases, of whom 24.4% (95/389) were nulliparous. In total, there were five cases from four twin pregnancies. One twin pair was concordant for Trisomy 21; the remaining three twin cases were Trisomy 21 with the other twin in the pregnancy unaffected. A total of 2.5% (10/394) of women were known to have had infertility treatment, half of whom had in vitro fertilization. Of these 10 cases, six were Trisomy 21 and the remaining four cases were Trisomy 18; the pregnancy outcome for these cases was six live births, two foetal deaths and two TOPFA.
The karyotype was known for 94.7% (373/394) of all cases. Of these, 2.2% (8/373) were mosaic and 1.9% (7/373) were 
Estimation of national total of trisomy affected pregnancies
The estimated total number of trisomy affected pregnancies nationally based on the risk by single year of age (not shown) from the observed study data in the East of Ireland was 1035 for the 3-year period, approximating to 345 per year. Of these, there were an estimated 254 cases of Trisomy 21 per year and an estimated 91 cases of Trisomies 18/13 combined.
Discussion Main findings
This study is the first to provide precise data on the three main trisomies in a large region of Ireland in the last 25 years. We observed higher numbers and total prevalence rates of Trisomies 21, 18 and 13 than previously reported. 5 The rates for each trisomy (35.7, 9.3 and 3.7/10 000 for Trisomies 21, 18 and 13, respectively) are among the highest in Europe, representing the advancing maternal age profile in Ireland. The high proportions of livebirths reflect cultural and social norms.
Although our study showed that 30% of Trisomies 21 and 18 affected pregnancies were in mother's aged under 35 years, the vast majority were associated with advancing maternal age; translocations and mosaic karyotypes were <5%. The risk of a trisomy affected pregnancy increased substantially in the 30-34 year age group, and steeply from 35+ years, confirming previous study findings. The last similar study 6 in this region was on 1980s data for Trisomy 21 and showed a total prevalence of 18.5/10 000 births. The almost doubling of the Trisomy 21 total prevalence rate since then is largely attributable to the changed maternal age profile rather than better ascertainment in our study, as prenatal diagnosis and subsequent TOPFA was extremely infrequent in 1980s Ireland.
Although 95% of Trisomies 18/13 cases were diagnosed prenatally, only 47% of Trisomy 21 cases had a prenatal diagnosis and this accounted for an overall prenatal diagnosis of 60%. However, as Trisomy 18/13 cases are more likely to have additional anomalies than Trisomy 21, a higher prenatal detection rate for Trisomies 18/13 is therefore not surprising. Notwithstanding this, while there is no national prenatal screening policy for congenital anomalies in the Republic of Ireland, the major university teaching hospitals generally undertake a congenital anomaly scan at around 20 weeks gestation. As the study region's maternity hospitals are university teaching hospitals, the prenatal detection rate for Trisomy 21 is comparable with other European countries such as Norway, Hungary, Portugal, the Netherlands and England/Wales, where prenatal diagnosis of Trisomy 21 ranged from 55 to 64% between 2008 and 2012.
7, 8 The 95% prenatal detection rate for Trisomies 18/13 in our study is similar to that elsewhere in Europe. Nevertheless, prenatal diagnosis in the East of Ireland is higher than other parts; in the South of Ireland, a Trisomy 21 prenatal detection rate of 14-23% was reported for 2008-2012, 7,9 although higher for Trisomies 18/13 at 62-78%.
The pregnancy outcome was a live birth in half of all cases, mostly Trisomy 21. More than 50% of Trisomy 18 and 66% of Trisomy 13 pregnancies resulted in a TOPFA, compared to 31% for Trisomy 21, the latter being less likely to be prenatally diagnosed. The perinatal mortality rate for each trisomy was higher than reported in a recent European study, 5 e.g. for Trisomy 21 (2.4 versus 0.7), and likely resulted from the larger proportion of live births/stillbirths in Ireland.
We estimated the total number of trisomy affected pregnancies in the Republic of Ireland based on the risk by individual year of maternal age. This gave a useful and fairly accurate indication of the number of affected pregnancies, though the number of live births cannot be accurately determined from this estimate as numbers differ within regions of Ireland and is also dependent on the availability of prenatal diagnosis.
What is already known on the topic
Advancing maternal age is a critical factor in determining the risk of a trisomy affected pregnancy and varies considerably throughout the world. Within Europe, EUROCAT data 10 show that from 2008 to 2012 the total prevalence rate of Trisomy 21 in the Zagreb area of Croatia was 13/10 000 births compared with 35/10 000 in the Mainz area of Germany. In the UK, the rate in Wessex was 30.0 from 2008 to 2012, compared with 23.8 in Northern England and 22.2 in Wales. Unlike most other countries in Europe, Ireland has been one of the top two countries for the proportion of births to mother's aged 35+ years from 1993 to 2013. 2 The total prevalence rates in our study are~25% higher than reported previously due to our inclusion of TOPFA cases. We also included a small proportion of prenatally diagnosed miscarriage cases under 20 weeks gestation, normally excluded by EUROCAT which records only TOPFA cases under 20 weeks gestation, thereby slightly inflating our rates compared with EUROCAT rates.
The high proportion of Trisomy 21 live births has implications for all health, educational and social services, unlike Trisomies 18/13 with their very high perinatal and neonatal mortality.
What this study adds
Our study provides the most up-to-date precise data on trisomy total prevalence in the largest region providing congenital anomaly surveillance in Ireland. The multiple methods of ascertainment we used were comprehensive. Information on trisomy affected births where the outcome was a TOPFA were ascertained for the first time. Our study also provided a reliable estimate of the total annual number of trisomy affected pregnancies in the Republic of Ireland, which was not previously available.
We showed that prenatal diagnosis has a major impact on pregnancy outcome, increasing the proportion of affected pregnancies that end in a TOPFA, irrespective of a likely lethal outcome as with Trisomies 18/13, or unlikely as with Trisomy 21, or of the situation in Ireland with TOPFA not permitted. Notwithstanding this, the fact that >60% of Trisomy 21 cases were live-born reflects both the desire of a high proportion of mother's to continue with their pregnancy and give birth, as well as reflecting prenatal diagnostic practises. Our study also confirms a high live-born proportion of trisomy births compared with Europe, and one of the highest total prevalence rates for trisomies, with implications for health, educational and social care providers and planners.
Other Irish studies 9,11 of trisomy affected pregnancies have shown only live and stillbirth data. Their data would not be as fully inclusive, particularly in the last 15 years with increasing use of prenatal diagnosis. We found that the proportion of trisomy cases where the outcome was a TOPFA was nearly 38% overall and this concurs with the TOPFA proportion of 23% in a study of neural tube defects in Ireland in 2013. 12 
Limitations of study
In calculating total prevalence rates, we did not apply an adjustment to each TOPFA case for early prenatal diagnoses (e.g. 12-15 weeks gestation) to correct for trisomy cases that ended in TOPFA that might otherwise have been an early foetal death/miscarriage. Such an adjustment, undertaken in a multicentred European study on trisomies 5 was found to have little impact on total prevalence rates. We included early foetal deaths/miscarriages to give a truer estimate of the risk of having a trisomy affected pregnancy.
While karyotyping is normally undertaken in the regional cytogenetics laboratory in Dublin, some clinicians referred samples to overseas laboratories, though the results were available for the study. The absence of a national cytogenetic centre catering for all karyotyping is challenging for the public health ascertainment of chromosomal anomalies at a national and regional level.
A minor logistical issue limited ascertainment by no >2% in total in one maternity hospital. It is also possible that some trisomy cases may have been missed following diagnoses made in private clinics that subsequently had a TOPFA outcome, though we estimate the number is negligible, as most of these cases would be referred to the main maternity hospitals for confirmation of diagnosis.
Conclusion
This study shows the first complete data on trisomy affected pregnancies in a large region of Ireland, and found high total prevalence rates of all three trisomies. The outcome in a high proportion was a live birth, particularly Trisomy 21, which has important consequences for individuals born with trisomies, their families, support groups and health services. Prenatal diagnosis was significantly higher for Trisomies 18 and 13 compared with Trisomy 21. Prenatal diagnosis also has an important impact on the decision making of some mother's with affected pregnancies. The study also provided a reliable estimate of the numbers of trisomy affected births in the Republic of Ireland.
